Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

AACR 2021 | Future treatment of relapsed iNHL

Matthew Matasar • 12 Apr 2021
AACR 2021
Lymphoma Non-Hodgkin Lymphoma Antibodies Copanlisib Rituximab

Matthew Matasar, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the future treatment of indolent non-Hodgkin lymphoma (iNHL), highlighting the use of copanlisib and rituximab in combination. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

Disclosures

Matthew Matasar, MD, has received support and honoraria from Bayer and Roche.

More from Matthew Matasar

Infectious complications of CD20 x CD3 bispecific antibody therapy in patients with B-cell lymphoma 2:10
Infectious complications of CD20 x CD3 bispecific antibody therapy in patients with B-cell lymphoma
Matthew Matasar • 23 Jun 2025
The role of alloSCT for R/R DLBCL in the era of CAR-T and bispecifics 2:31
The role of alloSCT for R/R DLBCL in the era of CAR-T and bispecifics
Matthew Matasar • 23 Jun 2025
Results of the Phase III POLARGO trial: POLA-R-GEMOX for the treatment of R/R DLBCL 2:35
Results of the Phase III POLARGO trial: POLA-R-GEMOX for the treatment of R/R DLBCL
Matthew Matasar • 23 Jun 2025
Results from the Phase III POLARGO trial: Pola-R-GemOx vs R-GemOx for R/R DLBCL 4:55
Results from the Phase III POLARGO trial: Pola-R-GemOx vs R-GemOx for R/R DLBCL
Matthew Matasar • 14 Jun 2025

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals